Your browser doesn't support javascript.
loading
Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry.
Bjartell, Anders; Lumen, Nicolaas; Maroto, Pablo; Paiss, Thomas; Gomez-Veiga, Francisco; Birtle, Alison; Kramer, Gero; Kalinka, Ewa; Spaëth, Dominique; Feyerabend, Susan; Matveev, Vsevolod; Lefresne, Florence; Lukac, Martin; Wapenaar, Robert; Costa, Luis; Chowdhury, Simon.
Afiliación
  • Bjartell A; Department of Urology, Skåne University Hospital Malmö, Jan Waldenströms gata 5, SE 205 02, Malmö, Sweden. anders.bjartell@med.lu.se.
  • Lumen N; Department of Translational Medicine, Medical Faculty, Lund University, Malmö, Sweden. anders.bjartell@med.lu.se.
  • Maroto P; Department of Urology, Ghent University Hospital, Ghent, Belgium.
  • Paiss T; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
  • Gomez-Veiga F; Urologie team Ulm, Ulm, Germany.
  • Birtle A; Urology Department and Kidney Transplant Unit, Translational Research Group of Urology GITUR-IBSAL, Salamanca University Hospital, Salamanca, Spain.
  • Kramer G; Royal Preston Hospital, Preston, UK.
  • Kalinka E; Department of Urology, Medical University of Vienna, Vienna, Austria.
  • Spaëth D; Clinic of Oncology, Polish Mother's Memorial Hospital, Research Institute, Lodz, Poland.
  • Feyerabend S; Centre d'Oncologie de Gentilly, Nancy, France.
  • Matveev V; Studienpraxis Urologie, Nürtingen, Germany.
  • Lefresne F; N.N. Blokhin National Cancer Research Center, Moscow, Russia.
  • Lukac M; EMEA Oncology, Janssen Pharmaceutica N.V., Beerse, Belgium.
  • Wapenaar R; Parexel International Czech Republic s.r.o, on behalf of Janssen Pharmaceutica N.V., Beerse, Belgium.
  • Costa L; Janssen-Cilag B.V., Breda, The Netherlands.
  • Chowdhury S; Oncology Division, Faculdade de Medicina, Hospital de Santa Maria, Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal.
Target Oncol ; 16(3): 357-367, 2021 05.
Article en En | MEDLINE | ID: mdl-33826036
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_prostate_cancer Asunto principal: Prednisona / Neoplasias de la Próstata Resistentes a la Castración / Acetato de Abiraterona Tipo de estudio: Clinical_trials / Observational_studies Límite: Aged / Humans / Male Idioma: En Revista: Target Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Suecia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_prostate_cancer Asunto principal: Prednisona / Neoplasias de la Próstata Resistentes a la Castración / Acetato de Abiraterona Tipo de estudio: Clinical_trials / Observational_studies Límite: Aged / Humans / Male Idioma: En Revista: Target Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Suecia